Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

Ítems similars

• Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
  per: Su, Po-Lan, et al.
  Publicat: (2018)
• Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan
  per: Yang, Szu-Chun, et al.
  Publicat: (2020)
• First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
  per: Su, Po‐Lan, et al.
  Publicat: (2020)
• Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
  per: Liang, Sheng-Kai, et al.
  Publicat: (2017)
• Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
  per: OuYang, Pu-Yun, et al.
  Publicat: (2013)